Late Breaking Science

Abstract 5000: A phase 3 trial with a 2×2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1. Abstract 5002: Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated ... Read more

Abstract LBA4: Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Abstract 5046: ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

Abstract 5020: Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.

Abstract 5072: Real-world first-line treatment patterns in patients with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.